Skip to main content
. 2024 Jan 31;249:10021. doi: 10.3389/ebm.2024.10021

TABLE 2.

Treatment-related adverse events.

n (%) Grade 1/2 Grade 3
*Injection site reaction 14 (45%)
Fatigue 7 (23%)
Nausea 5 (16%)
Diarrhoea 3 (10%)
Lymphocytopenia 3 (10%)
ALP elevation 1 (3%) 1 (3%)
Anaemia 2 (6%)
Anorexia 2 (6%)
Weight loss 2 (6%)

Adverse events reported as related to study medications in more than one patient.

No grade 4 events were observed.

ALP, alkaline phosphatase.

*Injection site reaction includes erythema, oedema, pruritis and discharge.